{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:07:20Z","timestamp":1788930440768,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Few direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and tolerability of DLX with PGB and GBP in DPNP, using placebo as a common comparator.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched PubMed, EMBASE, CENTRAL databases and regulatory websites for randomized, double-blind, placebo-controlled, parallel group or crossover clinical trials (RCTs) assessing DLX, PGB, GBP and AMT in DPNP. Study arms using approved dosages with assessments after 5\u201313 weeks were eligible. Efficacy criteria were: reduction in 24-hour pain severity (24 h PS) for all three drugs, and response rate (\u2265 50% pain reduction) and Patient Global Impression of Improvement\/Change (PGI-I\/C) for DLX and PGB only. Tolerability criteria included: discontinuation, diarrhoea, dizziness, headache, nausea and somnolence. Direct comparisons versus placebo were conducted with pooled fixed \u2013 and random-effects analyses on endpoints reported in at least two studies of each drug. Indirect comparisons were performed between DLX and each of PGB and GBP using Bayesian simulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three studies of DLX, six of PGB, two of GBP and none of AMT met the inclusion criteria. In random-effects and fixed-effects analyses of DLX, PGB and GBP, all were superior to placebo for all efficacy parameters, with some tolerability trade-offs. Indirect comparison of DLX with PGB found no differences in 24 h PS, but significant differences in PGI-I\/C, favouring PGB, and in dizziness, favouring DLX were apparent. Comparing DLX and GBP, there were no statistically significant differences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>From the few available studies suitable for indirect comparison, DLX shows comparable efficacy and tolerability to GBP and PGB in DPNP. Duloxetine provides an important treatment option for this disabling condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-9-6","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T19:12:58Z","timestamp":1234293178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":184,"title":["Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain"],"prefix":"10.1186","volume":"9","author":[{"given":"Sibilia","family":"Quilici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"L\u00f6thgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trong Kim","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garcia-Cebrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Monz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,10]]},"reference":[{"key":"220_CR1","volume-title":"Classification of Chronic Pain","author":"IASP Task Force on Taxonomy","year":"1994","unstructured":"IASP Task Force on Taxonomy: Classification of Chronic Pain. 1994, Seattle: IASP Press, 2","edition":"2"},{"key":"220_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1464-5491.2004.01271.x","volume":"21","author":"C Daousi","year":"2004","unstructured":"Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabetic Medicine. 2004, 21: 976-982.","journal-title":"Diabetic Medicine"},{"key":"220_CR3","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2337\/diacare.24.9.1584","volume":"24","author":"CL Leibson","year":"2001","unstructured":"Leibson CL, Williamson DF, Melton LJ, Palumbo PJ, Smith SA, Ransom JE, et al: Temporal trends in BMI among adults with diabetes. Diabetes Care. 2001, 24: 1584-1589.","journal-title":"Diabetes Care"},{"key":"220_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2288-1-2","volume":"1","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001, 1: 2-","journal-title":"BMC Med Res Methodol"},{"key":"220_CR5","first-page":"76","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W: ECDEU assessment manual for psychopharmacology, revised. 1976, Rockville, MD, US Department of Health, Education, and Welfare publication (ADM), National Institute of Mental Health, 76-338."},{"key":"220_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG: Confidence intervals for the number needed to treat. BMJ. 1998, 317: 1309-1312.","journal-title":"BMJ"},{"key":"220_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/0470854200","volume-title":"Meta-analysis of controlled clinical trials","author":"A Whitehead","year":"2002","unstructured":"Whitehead A: Presentation and interpretation of results. Meta-analysis of controlled clinical trials. 2002, Chichester: Wiley, 194-196."},{"key":"220_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001, 94: 149-158.","journal-title":"Pain"},{"key":"220_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00002508-199712000-00009","volume":"13","author":"M Vrethem","year":"1997","unstructured":"Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell LH: A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 1997, 13: 313-323.","journal-title":"Clin J Pain"},{"key":"220_CR10","volume-title":"F1J-MC-HMAW Study Report (internal)","author":"Eli Lilly and Company","year":"2004","unstructured":"Eli Lilly and Company: F1J-MC-HMAW Study Report (internal). 2004"},{"key":"220_CR11","volume-title":"F1J-MC-HMAV Study Report (internal)","author":"Eli Lilly and Company","year":"2004","unstructured":"Eli Lilly and Company: F1J-MC-HMAV Study Report (internal). 2004"},{"key":"220_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998, 280: 1831-1836.","journal-title":"JAMA"},{"key":"220_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","volume":"3","author":"DA Simpson","year":"2001","unstructured":"Simpson DA: Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease. 2001, 3: 53-62.","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"220_CR14","unstructured":"European Medicines Agency (EMEA): Lyrica \u2013 European Public Assessment Report. Scientific Discussion. [http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/lyrica\/lyricaM2.htm]"},{"key":"220_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004, 110: 628-638.","journal-title":"Pain"},{"key":"220_CR16","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"H Lesser","year":"2004","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004, 63: 2104-2110.","journal-title":"Neurology"},{"key":"220_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","volume":"105","author":"CP Watson","year":"2003","unstructured":"Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J: Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003, 105: 71-78.","journal-title":"Pain"},{"key":"220_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","volume":"60","author":"JS Gimbel","year":"2003","unstructured":"Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003, 60: 927-934.","journal-title":"Neurology"},{"key":"220_CR19","first-page":"20","volume-title":"European Neurological Disease","author":"E Eisenburg","year":"2006","unstructured":"Eisenburg E: Management of neuropathic pain. European Neurological Disease. 2006, 20-23."},{"key":"220_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","volume":"118","author":"NB Finnerup","year":"2005","unstructured":"Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005, 118: 289-305.","journal-title":"Pain"},{"key":"220_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0304-3959(96)03140-5","volume":"68","author":"HJ McQuay","year":"1996","unstructured":"McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA: A systematic review of antidepressants in neuropathic pain. Pain. 1996, 68: 217-227.","journal-title":"Pain"},{"key":"220_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1468-1331.2006.01511.x","volume":"13","author":"N Attal","year":"2006","unstructured":"Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006, 13: 1153-1169.","journal-title":"Eur J Neurol"},{"key":"220_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005, 116: 109-118.","journal-title":"Pain"},{"issue":"Suppl A","key":"220_CR24","doi-asserted-by":"publisher","first-page":"16A","DOI":"10.1155\/2006\/651712","volume":"11","author":"I Gilron","year":"2006","unstructured":"Gilron I, Flatters SJ: Gabapentin and pregabalin for the treatment of neuropathic pain: A review of laboratory and clinical evidence. Pain Res Manag. 2006, 11 (Suppl A): 16A-29A.","journal-title":"Pain Res Manag"},{"key":"220_CR25","unstructured":"Hadj Tahar A: Pregabalin for peripheral neuropathic pain. 2005, Ottawa, Canadian Coordinating Office for Health Technology Assessment. Issues in emerging health technologies, 67"},{"issue":"6","key":"220_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0885-3924(00)00218-9","volume":"20","author":"SL Collins","year":"2000","unstructured":"Collins SL, Moore RA, McQuay HJ, Wiffen P: Antidepressants and anticonvulsants for diabetic neuropathy postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000, 20 (6): 449-458.","journal-title":"J Pain Symptom Manage"},{"key":"220_CR27","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJM199205073261904","volume":"326","author":"MB Max","year":"1992","unstructured":"Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992, 326: 1250-1256.","journal-title":"N Engl J Med"},{"key":"220_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.37.4.589","volume":"37","author":"MB Max","year":"1987","unstructured":"Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987, 37: 589-596.","journal-title":"Neurology"},{"key":"220_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001, 135: 982-989.","journal-title":"Ann Intern Med"},{"key":"220_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003, 326: 472-","journal-title":"BMJ"},{"key":"220_CR31","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006, 67: 1411-1420.","journal-title":"Neurology"},{"key":"220_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005, 6: 346-356.","journal-title":"Pain Med"},{"key":"220_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible \u2013 and fixed-dose regimens. Pain. 2005, 115: 254-263.","journal-title":"Pain"},{"key":"220_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, Portenoy R, Sharma U, LaMoreaux L, Bockbrader H, Knapp LE: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005, 6: 253-260.","journal-title":"J Pain"},{"key":"220_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","volume":"12","author":"T Tolle","year":"2008","unstructured":"Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP: Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008, 12: 203-213.","journal-title":"Eur J Pain"},{"key":"220_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-8-33","volume":"8","author":"JC Arezzo","year":"2008","unstructured":"Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L: Efficacy and safety of pregabalin 600 mg\/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008, 8: 33-","journal-title":"BMC Neurol"},{"key":"220_CR37","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2337\/dc07-2105","volume":"31","author":"R Freeman","year":"2008","unstructured":"Freeman R, Durso-Decruz E, Emir B: Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008, 31: 1448-1454.","journal-title":"Diabetes Care"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-9-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-9-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-9-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-9-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:22:17Z","timestamp":1630448537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-9-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-9-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,10]]},"assertion":[{"value":"31 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}